Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Total 13F shares
-
38,834,584
-
Share change
-
+2,213,227
-
Total reported value
-
$149,117,927
-
Put/Call ratio
-
145%
-
Price per share
-
$3.84
-
Number of holders
-
59
-
Value change
-
+$3,748,609
-
Number of buys
-
34
-
Number of sells
-
32
Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q4 2022
As of 31 Dec 2022,
ADC Therapeutics SA - Common Shares (ADCT) was held by
59 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
38,834,584 shares.
The largest 10 holders included
Redmile Group, LLC, FMR LLC, MILLENNIUM MANAGEMENT LLC, JPMORGAN CHASE & CO, ALLIANCEBERNSTEIN L.P., GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC, EVENTIDE ASSET MANAGEMENT, LLC, BANK OF AMERICA CORP /DE/, and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
59
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.